Company / Cost of Revenue
Organon & Co. Cost of Revenue History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$2.9B
FY2025
5-year range
$2.3B / $2.9B
FY2021-FY2025
Trend
+8.0%
vs FY2024
Sector context
#11 of 85
Health Care
What the data says
Organon & Co.'s cost of revenue of $2.9B is higher than 87% of companies in the Health Care sector (FY2025). Cost of Revenue has increased for 5 consecutive years, from $2.1B in FY2020 to $2.9B in FY2025.
Based on SEC 10-K filings.
$2.9B in FY2025 with a 5-year CAGR of +6.5%. Top quartile in the Health Care sector.
Increased from $2.5B to $2.9B over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +8.2%
- 5-Year CAGR
- +6.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 85This company $2.9B Sector average $2.0B
▼
+46.4% above sector average
Key checks
Key Insights
- Organon & Co.'s cost of revenue has grown for 5 consecutive years.
- 5-year CAGR of +6.5%, indicating consistent growth.
- In FY2025, cost of revenue increased 8.0% year-over-year.
- Ranks #11 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 55.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.9B | +8.0% |
| FY2024 | $2.7B | +6.9% |
| FY2023 | $2.5B | +9.6% |
| FY2022 | $2.3B | +0.9% |
| FY2021 | $2.3B | +7.3% |
| FY2020 | $2.1B | -6.8% |
| FY2019 | $2.3B | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026